Belle Health Review: GLP-1 Care, Longevity Claims and Pharmacy Details

The longevity claims need a closer look

Belle now promotes sleep and recovery benefits for sermorelin. This is more than a description of growth-hormone signaling. The public product page does not identify a controlled study of its prescribed regimen supporting those outcomes. ⁴

There is relevant human research, so saying that no adult study exists would be wrong. A 1997 study involved 19 older adults receiving a GHRH analog. It reported increased lean body mass in men, not women; sleep quality was unchanged in both groups. That small, specific study does not establish that Belle's compounded treatment improves sleep or recovery for a broader customer population. ⁸

For NAD+, the product page promotes clearer thinking and energy. A biological role in cellular metabolism is not itself evidence that a subcutaneous injection improves how a person feels. The cited 2019 human pilot tracked NAD+ metabolites during an intravenous infusion; it did not establish the focus, fatigue or recovery benefits advertised for Belle's subcutaneous product. Route and outcome both differ. ^{5 9}

The pharmacy is named, but the exact order still matters

Belle's dedicated pharmacy page identifies Hillstone and OptioRx for compounded GLP-1s; Hillstone also appears for several longevity products. It lists The Pharmacy Hub for skin and hair products, and identifies BPI Labs and Olympia separately as manufacturers. These are Belle's disclosures, not independent verification of every license or facility standard. ⁶

The treatments page shows a shorter partner list. The terms, labeled July 2025, still name VitalRx and omit some partners on the newer pharmacy page. That difference is a reason to ask which pharmacy will fill the actual prescription, not evidence that an unnamed pharmacy is being used. Belle says the filling pharmacy appears on the medication label and availability depends on the state. ^{6 7 10}

A starting price is not the complete commitment

The treatment table checked October 18 lists semaglutide at $109 a month on twelve months and $199 for one month. Tirzepatide is $179 a month on twelve months and $249 for one. NAD+ is $149 a month on three months or $199 for one; sermorelin is $119 a month on a three-month supply. Those supply labels identify the price commitment, but confirm the total charge and payment schedule before choosing a plan. ^{3 4 5 10}

Belle says clinician oversight, support and shipping are included. Its cancellation language should be read with the terms: subscriptions may renew unless canceled before renewal, and shipped prescription products are not refundable under the published policy. It asks customers to report an incorrect or defective product within seven days of delivery. That is Belle's policy, not a universal rule about prescription refunds. ^{7 10}

What the FDA letter actually concerns

The February 2026 warning letter concerns pictured semaglutide and tirzepatide labels that suggested Belle was the compounder. It does not report a potency, contamination or sterility finding. Belle's current pages explicitly distinguish the practice from the compounding pharmacy. That disclosure does not, by itself, establish FDA resolution of the letter. ^{11 3}

What to clarify before buying

Ask for the prescribed formulation, filling pharmacy, total commitment and renewal terms. For a longevity treatment, ask what evidence supports the particular outcome you want, how it will be assessed and when the clinician would stop treatment if it does not help. Published pharmacy names and an accessible price are useful service disclosures; they cannot substitute for evidence of benefit. ^{6 7}